Publicacións nas que colabora con TOMAS M. M. GARCIA-CABALLERO PARADA (6)

2024

  1. Edoxaban treatment in a post-infarction experimental model

    European Journal of Pharmacology, Vol. 962

2022

  1. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2020

  1. Author Correction: Identification and characterization of Cardiac Glycosides as senolytic compounds (Nature Communications, (2019), 10, 1, (4731), 10.1038/s41467-019-12888-x)

    Nature Communications

  2. Laser-induced transient skin disruption to enhance cutaneous drug delivery

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 156, pp. 165-175

2019

  1. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

    Biochemical Pharmacology, Vol. 170

2003

  1. Serotonin upregulates the activity of phagocytosis through 5-HT 1A receptors

    British Journal of Pharmacology, Vol. 139, Núm. 2, pp. 457-463